OUR COMPANIES / Life Sciences

CardioDX

www.cardiodx.com
Board Members: Bill Ericson
Initiatives: Life Sciences
Ticker: Private

Genomic insight for cardiovascular symptoms

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, develops clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is expanding patient access and improving healthcare quality and efficiency through the commercialization of genomic technologies.

The Corus™ CAD gene expression test helps clinicians confidently identify which of their stable chest pain patients are likely to need further assessment for obstructive coronary artery disease (CAD). The test involves a routine blood draw conveniently administered in any clinician’s office and does not expose patients to risks of radiation or imaging agent intolerance.

Facts & Statistics

Maker of the world’s first and only clinically validated blood-based test for obstructive coronary artery disease, one of the single largest diagnostic markets in medicine.
Launched Corus CAD in the U.S. in June 2009; was used 3,300 times by 225 cardiologists and primary care clinicians in the first year of commercialization.
Corus CAD is the first sex-specific test for obstructive coronary artery disease to directly account for critical biological differences in cardiovascular disease between men and women.
Developed and validated in the PREDICT prospective multi-center U.S. trial, Corus CAD integrates the expression levels of 23 genes and other patient characteristics clinically validated to indicate obstructive CAD.
The PREDICT trial and the company’s scientific work has been published in Annals of Internal Medicine, Circulation Cardiovascular Genetics and the Journal of the American College of Cardiology.

Mohr Davidow

INITIATIVES

All Companies

OUR COMPANIES / Life Sciences

CardioDX

Facts & Statistics